Molecular Subtypes of Pancreatic Cancer: A Proteomics Approach.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33853864.
- Also identified by DOI 10.1158/1078-0432.CCR-21-0640 and PMC identifier 8197741.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Through molecular subtyping, therapeutic vulnerabilities can be exploited for developing personalized medicine. The real utility of molecular subtyping lies in the clinical translation for disease characterization. Proteomic methods with defined marker sets hold great promise for improving therapy outcomes by improving the speed of predictions for devising treatment strategies.<i>See related article by Son et al., p. 3370</i>.
Medical subject headings
- Pancreatic Neoplasms
- Proteomics